Cargando…

Integrated flow-through purification for therapeutic monoclonal antibodies processing

An integrated all flow-through technology platform for the purification of therapeutic monoclonal antibodies (mAb), consisting of activated carbon and flow-through cation and anion exchange chromatography steps, can replace a conventional chromatography platform. This new platform was observed to ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Ichihara, Takamitsu, ITO, Takao, Kurisu, Yasuhiko, Galipeau, Kevin, Gillespie, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5825194/
https://www.ncbi.nlm.nih.gov/pubmed/29271693
http://dx.doi.org/10.1080/19420862.2017.1417717
_version_ 1783302163076743168
author Ichihara, Takamitsu
ITO, Takao
Kurisu, Yasuhiko
Galipeau, Kevin
Gillespie, Christopher
author_facet Ichihara, Takamitsu
ITO, Takao
Kurisu, Yasuhiko
Galipeau, Kevin
Gillespie, Christopher
author_sort Ichihara, Takamitsu
collection PubMed
description An integrated all flow-through technology platform for the purification of therapeutic monoclonal antibodies (mAb), consisting of activated carbon and flow-through cation and anion exchange chromatography steps, can replace a conventional chromatography platform. This new platform was observed to have excellent impurity clearance at high mAb loadings with overall mAb yield exceeding 80%. Robust removal of DNA and host cell protein was demonstrated by activated carbon and a new flow-through cation exchange resin exhibited excellent clearance of mAb aggregate with high monomer recoveries. A ten-fold improvement of mAb loading was achieved compared to a traditional cation exchange resin designed for bind and elute mode. High throughput 96-well plate screening was used for process optimization, focusing on mAb loading and solution conditions. Optimum operating windows for integrated flow-through purification are proposed based on performance characteristics. The combination of an all flow-through polishing process presents significant opportunities for improvements in facility utilization and process economics.
format Online
Article
Text
id pubmed-5825194
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-58251942018-03-01 Integrated flow-through purification for therapeutic monoclonal antibodies processing Ichihara, Takamitsu ITO, Takao Kurisu, Yasuhiko Galipeau, Kevin Gillespie, Christopher MAbs Report An integrated all flow-through technology platform for the purification of therapeutic monoclonal antibodies (mAb), consisting of activated carbon and flow-through cation and anion exchange chromatography steps, can replace a conventional chromatography platform. This new platform was observed to have excellent impurity clearance at high mAb loadings with overall mAb yield exceeding 80%. Robust removal of DNA and host cell protein was demonstrated by activated carbon and a new flow-through cation exchange resin exhibited excellent clearance of mAb aggregate with high monomer recoveries. A ten-fold improvement of mAb loading was achieved compared to a traditional cation exchange resin designed for bind and elute mode. High throughput 96-well plate screening was used for process optimization, focusing on mAb loading and solution conditions. Optimum operating windows for integrated flow-through purification are proposed based on performance characteristics. The combination of an all flow-through polishing process presents significant opportunities for improvements in facility utilization and process economics. Taylor & Francis 2018-01-16 /pmc/articles/PMC5825194/ /pubmed/29271693 http://dx.doi.org/10.1080/19420862.2017.1417717 Text en © 2018 The Author(s). Published with license by Taylor and Francis group, LLC http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Report
Ichihara, Takamitsu
ITO, Takao
Kurisu, Yasuhiko
Galipeau, Kevin
Gillespie, Christopher
Integrated flow-through purification for therapeutic monoclonal antibodies processing
title Integrated flow-through purification for therapeutic monoclonal antibodies processing
title_full Integrated flow-through purification for therapeutic monoclonal antibodies processing
title_fullStr Integrated flow-through purification for therapeutic monoclonal antibodies processing
title_full_unstemmed Integrated flow-through purification for therapeutic monoclonal antibodies processing
title_short Integrated flow-through purification for therapeutic monoclonal antibodies processing
title_sort integrated flow-through purification for therapeutic monoclonal antibodies processing
topic Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5825194/
https://www.ncbi.nlm.nih.gov/pubmed/29271693
http://dx.doi.org/10.1080/19420862.2017.1417717
work_keys_str_mv AT ichiharatakamitsu integratedflowthroughpurificationfortherapeuticmonoclonalantibodiesprocessing
AT itotakao integratedflowthroughpurificationfortherapeuticmonoclonalantibodiesprocessing
AT kurisuyasuhiko integratedflowthroughpurificationfortherapeuticmonoclonalantibodiesprocessing
AT galipeaukevin integratedflowthroughpurificationfortherapeuticmonoclonalantibodiesprocessing
AT gillespiechristopher integratedflowthroughpurificationfortherapeuticmonoclonalantibodiesprocessing